P/E của cổ phiếu VRTX là bao nhiêu?

VERTEX PHARMACEUTICALS INC (VRTX) hiện giao dịch ở mức P/E 28.18 lần.

ROE của cổ phiếu VRTX là bao nhiêu?

VERTEX PHARMACEUTICALS INC có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 22.41%.

Tỷ suất cổ tức của VRTX là bao nhiêu?

VERTEX PHARMACEUTICALS INC có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của VRTX là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của VRTX ở mức 77/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu VRTX không?

Điểm AI Timing của VRTX là 67/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu VRTX thuộc ngành nào?

VERTEX PHARMACEUTICALS INC được xếp vào ngành Healthcare >> Biotechnology trên sàn NASDAQ

Cổ phiếu VRTX (NASDAQ) | VERTEX PHARMACEUTICALS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

VRTX AI Analysis Summary

Our AI summary for VRTX: VERTEX PHARMACEUTICALS INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 28.18, ROE of 22.41%, a dividend yield of 0.00%. Its financial Quality Score stands at 77/100 — mid-range fundamentals relative to the market. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

VRTX

VERTEX PHARMACEUTICALS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 99

USD 477.10

-4.60 (-0.95%) Day Change

Watchlist Portfolio Compare Chart

28.18

P/E

0.37

D/E

22.4%

ROE

16.4%

ROA

0.00%

Div Yield

-0.09

PEG

VERTEX PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 477.10 Price -4.60 (-0.95%) Day Change	NEWS SCORE: 99

VRTX Chất lượng tổng thể của cố phiếu Tốt ( Chất lượng = 77) và Thời điểm mua ...(Sign In to See)...

Loading chart...

77 QUALITY

Signal: OUTPERFORM

Signal Description: Company financial health is Good

Reason: [-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt lắm , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Tốt , ...

Yếu tố Chất lượng

50%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	970
Magic Formula Rank by ROE	970
Magic Formula Rank by ROIC	1126
Price	477.10
PBV / Sector	6.31 / 5.20
Earning Per Share	16.93

PE / Sector	28.18 / 19.97
PEG or PE/Growth / Sector	-0.09 / 1.22
Average 1M Daily Value	694.51 M
Average 1W Daily Value	639.57 M

Yếu tố Kỹ thuật

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

54%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

72%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	35.40 / 98.71 GREAT
NPM Average (%) / Sector	27.43 / -1,721.76 GREAT
NPM Change Average (%) / Sector	-220.04 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	16.38 / 27.02 GOOD
ROA Average (%) / Sector	12.67 / -368.17
ROA Change Average (%) / Sector	-213.94 / 5,404.12
ROE (%) / Sector	22.41 / 3.47 GOOD
ROE Average (%) / Sector	16.96 / 6.51
ROE Change Average (%) / Sector	-218.18 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Chi tiết đăng ký

Analyze Date	2026-08-01 08:00:40
Symbol	VRTX
Name	VERTEX PHARMACEUTICALS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	253.81 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	122,258.08 / 9,903.94

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 50 Northern Avenue, Boston, MA, United States, 02210

Phone: 617 341 6100

Website: https://www.vrtx.com

Employees: 6,400

Sector: Healthcare >> Biotechnology

Description: Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.